AMENDMENTS TO THE CLAIMS

1.　(Previously Presented) A method of qualifying breast cancer in a subject comprising:

(a)　measuring at least one biomarker in a sample from a subject, and

(b)　correlating the measurement with breast cancer status,

wherein the biomarker is selected from the group consisting of:

Marker I (BC1)

Marker II (BC2)

Marker III (BC3)

Marker IV

Marker V

Marker VI

Marker VII

Marker VIII

Marker IX

Marker X

Marker XI

Marker XII

Marker XIII

Marker XIV,

and combinations thereof.

2.　(Previously Presented) The method of claim 1 further comprising:

(c)　managing subject treatment based on the status.

3.　(Previously Presented) The method of claim 2 wherein managing subject treatment is selected from ordering more rests, performing surgery, and taking no further action.

4.　(Previously Presented) The method of claim 2 further comprising:

(d)　measuring the at least one biomarker after subject management.

BOS2 658438.1

5.   (Previously Presented) The method of claim 1 wherein the breast cancer status is selected from the group consisting of the subject's risk of cancer, the presence or absence of disease, the stage of disease, and the effectiveness of treatment.

6.   (Previously Presented) The method of claim 1 wherein measuring comprises detecting by mass spectrometry.

7.   (Previously Presented) The method of claim 1 wherein at least one biomarker is selected from Marker I (BC1), Marker II (BC2), and Marker III (BC3).

8.   (Previously Presented) The method of claim 1 further comprising measuring a known breast cancer biomarker in a sample from the subject and correlating measurement of the known biomarker and the measurement of any one or more of Markers I through XIV with breast cancer status.

9.   (Previously Presented) The method of claim 8 wherein the known biomarker is selected from CA 15.3 or CA 27.29.

10.   (Previously Presented) The method of claim 1 comprising measuring Marker I (BC1), Marker II (BC2), and Marker III (BC3).

11.   (Previously Presented) The method of claim 10 further comprising measuring a known breast cancer biomarker in a sample from the subject and correlating measurement of the known biomarker and the measurement of any one or more of Markers I through XIV with breast cancer status.

12.   (Previously Presented) The method of claim 11 wherein the known biomarker is selected from CA 15.3 or CA 27.29.

13.   (Previously Presented) The method of claim 1 wherein measuring comprises:
(a)   providing a subject sample of blood or a blood derivative;

(b)   capturing one or more of Markers I through XIV from the sample on a surface of a

substrate comprising capture reagents that bind the protein biomarkers.

14.-15. (Canceled)

16.   (Previously Presented) The method of claim 13 wherein the substrate is a

microtiter plate comprising biospecific affinity reagents that bind one or more of Markers I

through XV and the protein biomarkers are detected by immunoassay.

17.   (Previously Presented) The method of claim 1 wherein measuring is selected

from detecting the presence or absence of the biomarkers(s), quantifying the amount of

marker(s), and qualifying the type of biomarker.

18.   (Previously Presented) The method of claim 1 wherein at least one biomarker is

measured using a biochip array.

19.   (Previously Presented) The method of claim 18 wherein the biochip array is a

protein chip array.

20.   (Canceled)

21.   (Previously Presented) The method of claim 18 wherein at least one biomarker is

immobilized on the biochip array.

22.   (Canceled)

23.   (Previously Presented) The method of claim 1 wherein the protein biomarkers are

measured by immunoassay.

24.   (Previously Presented) The method of claim 1 wherein the correlating is performed by a software classification algorithm.

25.   (Previously Presented) The method of claim 1 wherein the sample is selected from blood, serum and plasma.

26.   (Previously Presented) A method comprising:

(a) measuring a plurality of biomarkers in a sample from the subject, wherein the plurality of biomarkers is selected from the group consisting of:

        Marker I (BC1)

        Marker II (BC2)

        Marker III (BC3)

        Marker IV

        Marker V

        Marker VI

        Marker VII

        Marker VIII

        Marker IX

        Marker X

        Marker XI

        Marker XII

        Marker XIII, and

        Marker XIV.

27.   (Previously Presented) The method of claim 26 wherein the plurality includes Marker I (BC1), Marker II (BC2), and Marker III (BC3).

28.   (Previously Presented) The method of claim 26 further comprising measuring a known biomarker.

29.   (Previously Presented) The method of claim 26 wherein the known biomarker is selected from CA 15.3 or CA 27.29.

30.   (Previously Presented) The method of claim 26 wherein the protein biomarkers are detected by SELDI or immunoassay.

31.   (Previously Presented) The method of claim 26 wherein the sample is selected from blood, serum and plasma.

32.-36. (Cancelled)

37.-57. (Canceled)

58.   (New) 1.   A method of determining if a subject has breast cancer comprising:

(a)   measuring at least one biomarker in a sample from the subject, and

(b)   correlating the measurement with the presence or absence of breast cancer, wherein the biomarker is selected from the group consisting of:

Marker I (BC1)

Marker II (BC2)

Marker III (BC3)

Marker IV

Marker V

Marker VI

Marker VII

Marker VIII

Marker IX

Marker X

Marker XI

Marker XII

Marker XIII

Marker XIV,

and combinations thereof.